Wegovy manufacturer Ascendis Pharma has been tasked with supporting the development of a once-monthly GLP-1 drug.

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist for obesity Terns plans to initiate a Phase 2 clinical trial in early second quarter of 2025 with initial 12-week data expected in the ...

First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity Oral small molecule amylin receptor agonist ... GSBR-1290 as a potential best-in-class oral small molecule GLP-1 receptor (GLP1-R ...

In a deal worth up to $285 million initially for the lead program, Novo Nordisk will gain access to Ascendis’ TransCon ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist for obesity Terns plans to initiate a Phase 2 clinical trial in early second quarter of 2025 with initial 12-week data expected in ...

SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule ... class oral small ...

“Our progress in the third quarter was highlighted by the compelling topline results from our Phase 1 study of TERN-601 ... once-daily, oral GLP-1R agonist for the treatment of obesity and ...